Observational studyPloS one2025
Heparin improves the mortality of patients with non-pulmonary sepsis-associated ARDS: A MIMIC-IV database analysis based on propensity score matching.
Observational study in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current Insights into Clinical, Molecular, and Therapeutic Approaches to Acute Respiratory Distress Syndrome.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-pulmonary sepsis often induces Acute Respiratory Distress Syndrome (ARDS). Dysregulated inflammation and coagulation disorders play important roles in the development of non-pulmonary sepsis-associated ARDS (NPS-ARDS). Heparin, with its potential anticoagulant and anti-inflammatory properties, may be used in the treatment of NPS-ARDS.
methodsThis is a retrospective observational study that uses Structured Query Language (SQL) to extract clinical data of NPS-ARDS patients from the Medical Information Mart for Intensive Care (MIMIC)-IV database. Based on the dosage of heparin, patients were divided into three groups: low-dose heparin treatment group (0-5000u/d), medium-dose heparin treatment group (5000u-10000u/d), and high-dose heparin treatment group (greater than 10000u/d). Propensity score matching (1:1) was used to match similar patients from the NPS-ARDS patients who did not use heparin to each heparin treatment group. The study compares the effects of heparin at different dosages on short-term mortality (7-day, 28-day, and 60-day mortality) and one-year cumulative survival rate in NPS-ARDS patients.
resultsPSM reduced the impact of confounding factors on the results to some extent. Low and medium doses of heparin did not improve patient mortality. However, high-dose heparin improved the short-term mortality of NPS-ARDS patients (7-day mortality: 4.1% vs. 14.3%, P < 0.001; 28-day mortality: 9.4% vs. 22.6%, P < 0.001; 60-day mortality: 13.2% vs. 24.8%, P = 0.001) and one-year cumulative survival rate (Log Rank = 8.349, P = 0.004), but it also prolonged ICU stay (6.7 ± 6.2 days vs. 5.7 ± 4.8 days, P = 0.041) and invasive mechanical ventilation (11.7 ± 6.9 hours/day vs. 5.7 ± 4.8 hours/day, P < 0.001).
conclusionIn patients with NPS-ARDS, high-dose heparin was associated with significantly improved short- and long-term survival, albeit at the cost of prolonged ICU stay and mechanical ventilation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.